Szymon S.
- Country
- Poland
- Department
- Klinika Onkologii i Hematologii Dziecięcej
Research Overview
- International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents
- Phase 3 Study of Imatinib with Cytotoxic Chemotherapy in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Evaluation of Ruxolitinib Combined with AIEOP-BFM 2017 Chemotherapy in Pediatric Acute Lymphoblastic Leukemia with JAK/STAT Pathway Activation
Data & Insights
Has run more than one trial at 79 of 198 partner sites.
Specializations
Pediatric Leukemia Research
The investigator specializes in treating acute lymphoblastic leukemia (ALL) in pediatric populations, with particular emphasis on Philadelphia chromosome-positive ALL variants.
- Standard and high-risk ALL protocols
- Philadelphia chromosome-positive leukemia
- JAK/STAT pathway activation in ALL
Their work encompasses innovative treatment approaches combining targeted therapies with established chemotherapy protocols.
Special Population Studies
Focuses on specialized treatment protocols for distinct patient groups, including myeloid leukemia in children with Down syndrome and acute myeloid leukemia (AML) in children and adolescents.
- Down syndrome-associated leukemia
- Pediatric AML treatments
- Adolescent leukemia protocols
The investigator develops targeted therapeutic approaches for specific genetic and age-related variants of leukemia.
Advanced Therapeutic Applications
Implements novel therapeutic strategies including proteasome inhibitors and immunotherapy in leukemia treatment protocols.
- Targeted molecular therapies
- Immunotherapeutic approaches
- Treatment response monitoring
Their research integrates innovative therapeutic agents with established treatment protocols to enhance patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.